Toxicologic Pathology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Free Full Text Free
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Louden, C.
Right arrow Articles by Richardson, R. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Louden, C.
Right arrow Articles by Richardson, R. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Toxicologic Pathology, Vol. 34, No. 1, 19-26 (2006)
DOI: 10.1080/01926230500512076
© 2006 Society of Toxicologic Pathology

Articles

Biomarkers and Mechanisms of Drug-Induced Vascular Injury in Non-Rodents

Calvert Louden1,3, David Brott2,3, Anne Katein2, Thomas Kelly2, Sarah Gould1, Huw Jones1, Graham Betton1, Jean-Pierre Valetin1 and Rudy J. Richardson3

1 Departments of Safety Assessment, AstraZeneca Pharmaceuticals, Alderley Park, Cheshire, UK
2 Wilmington, Delaware 19850, USA
3 Toxicology Program, Department of Environmental Health Sciences, School of Public Health, University of Michigan, Ann Arbor, Michigan 48105, USA

Correspondence: Address correspondence to: Calvert Louden, Department of Safety Assessment-UK, Mereside, Alderley Park, Cheshire SK10 4TF, England; e-mail:calvert.louden{at}astrazeneca.com

In preclinical safety studies, drug-induced vascular injury can negatively impact candidate-drug selection because there are no obvious diagnostic markers for monitoring this pathology preclinically or clinically. Furthermore, our current understanding of the pathogenesis of this lesion is limited. While vasodilatation and increased shear stress appear to play a role, the exact mechanism(s) of injury to the primary target cells, smooth muscle (SMC) and endothelial cell (EC), are unknown. Evaluation of potential novel markers for clinical monitoring with a mechanistic underpinning would add value in risk assessment and risk management. This mini review focuses on the efforts and progress to identify diagnostic markers as well as understanding the mechanism of action in nonrodent drug-induced vascular injury.

Key Words: Drug-induced vascular injury • biomarker • von Willebrand Factor • von Willebrand Factor propeptide • caveolin-1 • nitric oxide

Abbreviations: AC, adenylyl cyclase • ADMA, asymetric dimethyl arginine • CRP, C-reactive protein • cav-1, caveolin-1 • CBF, coronary blood flow • DDAVP, 1-Deamino-8-Desmethylarginine vasopressin • EC, endothelial cells • ET, endothelin • ETRA, endothelin receptor antagonist • HR, heart rate • MAP, mean arterial pressure • NO, nitric oxide • NOS, nitric oxide synthase • PCO, potassium channel opener • SMA, smooth muscle {alpha} actin • SMC, smooth muscle cells • VEGF, vascular endothelial growth factor • vWF, von Willebrand factor • vWFpp, von Willebrand factor propeptide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?